Key result
A drug-coated balloon-based strategy lowered the 3-year risk of major adverse cardiovascular events compared to DES-only PCI.
Why the study?
Does a drug-coated balloon-based strategy reduce three-year MACE compared to second-generation drug-eluting stents in patients with de novo left anterior descending artery lesions?
Cohort (n=4,415)
Yes
Does a drug-coated balloon-based strategy reduce three-year MACE compared to second-generation drug-eluting stents in patients with de novo left anterior descending artery lesions?
Answers are grounded in this paper and cite their sources.
A drug-coated balloon-based strategy for de novo LAD lesions significantly reduces 3-year MACE, driven largely by reduced major bleeding, compared to a standard drug-eluting stent approach.
Drug-coated balloons (DCB) are increasingly utilized in percutaneous coronary intervention (PCI), but their effectiveness in coronary artery disease (CAD) needs further exploration. This study investigates the efficacy and safety of a DCB-based strategy for de novo left anterior descending artery (LAD) disease. Patients with de novo LAD lesions treated with DCB alone or combined with drug-eluting stents (DES) and were retrospectively enrolled from 2010 to 2023 (n = 268). The comparator group consisted of patients treated with second-generation DES from a Korean multicenter registry (n = 4,147). The primary endpoint was three-year major adverse cardiovascular events (MACE), including cardiac death, myocardial infarction, target vessel revascularization, target lesion thrombosis, and major bleeding. In the DCB-based group (n = 268), 218 (81.3%) received DCB-only, while 50 (18.7%) underwent a hybrid approach. After propensity score-matching of 243 paired subjects, baseline characteristics were balanced. The DCB-based PCI reduced overall stent burden by 86.7% and significantly lowered the risk of MACE at three years compared to DES-only PCI (4.5% vs. 7.6%, HR 0.50, 95% CI 0.28-0.90; p = 0.020). The most significant reduction was in major bleeding. The DCB-based approach offers an alternative to DES-only strategy for LAD PCI by reducing three-year MACE risk, supporting its use in treating de novo CAD.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2024) conducted a cohort in de novo left anterior descending artery disease (n=4,415). Drug-coated balloon-based treatment vs. Second-generation drug-eluting stents (DES) was evaluated on Three-year major adverse cardiovascular events (MACE), including cardiac death, myocardial infarction, target vessel revascularization, target lesion thrombosis, and major bleeding (HR 0.50, 95% CI 0.28-0.90, p=0.020). A drug-coated balloon-based strategy lowered the 3-year risk of major adverse cardiovascular events compared to DES-only PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: